Tequin and Maxillary sinusitis - a phase IV clinical study of FDA data
Summary:
We study 4,682 people who take Tequin (gatifloxacin) or have Maxillary sinusitis. No report of Maxillary sinusitis is found in people who take Tequin.
The phase IV clinical study is created by eHealthMe based on reports from the FDA, and is updated regularly.
What is Tequin?
Tequin has active ingredients of gatifloxacin. eHealthMe is studying from 4,645 Tequin users. Check the latest studies of Tequin.
What is Maxillary Sinusitis?
Maxillary sinusitis (infection of airspaces within the paranasal sinus) is found to be associated with 17 drugs and 18 conditions by eHealthMe. Check the latest studies of Maxillary sinusitis.
No report is found.
Do you take Tequin and have Maxillary sinusitis?
- Check whether Maxillary sinusitis is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously
Related studies:
Effectiveness of, long term effects of, and alternative drugs to Tequin:
- Tequin (4,645 reports)
Maxillary sinusitis treatments and more:
- Maxillary sinusitis (37 reports)
How severe was Maxillary sinusitis and when was it recovered:
Expand to all the drugs that have ingredients of gatifloxacin:
Browse all side effects of Tequin:
a b c d e f g h i j k l m n o p q r s t u v w x y zBrowse all the drugs that are associated with Maxillary sinusitis:
Browse all the conditions that are associated with Maxillary sinusitis:
How the study uses the data?
The study uses data from the FDA. It is based on gatifloxacin (the active ingredients of Tequin) and Tequin (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.
How to use the study?
DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.
Who is eHealthMe?
With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).
WARNING, DISCLAIMER, USE FOR PUBLICATION
WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.
DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.
If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.
Recent studies on eHealthMe:
- Could Acetylsalicylic Acid cause Facial Paresis? - 3 seconds ago
- Drug interactions of Diazepam and Senna Alexandrina - 6 seconds ago
- Prozac and Gastric Ulcer for Women aged 20-29 - 7 seconds ago
- Prozac and Peptic Ulcer for Women aged 20-29 - 8 seconds ago
- Prozac and Ulcer - Peptic for Women aged 20-29 - 8 seconds ago
- Prozac and Duodenal Ulcer for Women aged 20-29 - 9 seconds ago
- Prozac and Uric Acid for Women aged 20-29 - 9 seconds ago
- Prozac and Ulcer for Women aged 20-29 - 9 seconds ago
- Prozac and Ulcer - Stomach for Women aged 20-29 - 10 seconds ago
- Prozac and Stomach Ulcer for Women aged 20-29 - 10 seconds ago